FDAnews
www.fdanews.com/articles/165428-eisai-to-launch-liver-disease-reagent-kit-in-japan

Eisai to Launch Liver Disease Reagent Kit in Japan

June 25, 2014

Tokyo-based drugmaker Eisai and its diagnostics arm EIDIA announced Wednesday the Japanese launch of the Panassay IV-C [Latex], an in vitro reagent kit designed to determine human type IV collagen in serum — an indicator of liver disease.

EDIA was granted exclusive marketing rights to the kit by Japanese diagnostics and blood collection tube maker Sekisui Medical, which has marketed the device since 2003. Beginning July 2, Panassay IV-C [Latex] will be marketed by EIDIA, with Eisai assisting with promotional activities, the company says.

Measuring type IV collagen levels in serum helps to assess the progression of hepatic fibrosis, diagnose cirrhosis, decide proper treatment for Hepatitis C and predict the risk of developing cancer, Eisai says.

Collagen IV is a major element in the bloodstream that increases as liver fibrosis progresses. — Kellen Owings

Subscribe to Devices & Diagnostics Letter for complete coverage of the medical devices industry. Click here for more information.